Appeal 2007-2864
Application 10/747,798
1. A method of inhibiting the growth of a papillomavirus-transformed
cell in a hyperplastic lesion in a subject comprising topically administering
to said lesion a growth inhibiting amount of a composition comprising (a) an
expression cassette comprising a promoter, active in cells of said lesion,
operably linked to a polynucleotide encoding a p53 polypeptide, and (b) a
pharmaceutical preparation suitable for topical delivery, wherein expression
of said p53 polypeptide inhibits growth of said cell.
31. A mouthwash for inhibiting the growth of a papillomavirus
transformed cell in a hyperplastic lesion in a subject comprising (a) an
expression cassette comprising a promoter operably linked to a
polynucleotide encoding a p53 polypeptide, (b) a liquid carrier formulated
for oral delivery, and (c) a flavorant.
The Examiner relies upon the following references:
Nielsen 2001/0044420 Nov. 22, 2001
El-Deiry WO 99/66946 Dec. 29, 1999
Zhang WO 00/29024 May 25, 2000
Clayman, G. “Clinical protocol for wild type p53 gene induction in
premalignancies of squamous epithelium of the oral cavity via an adenoviral
vector,” PowerPoint presentation, March 2001.
Oda et al. “Chromosomal abnormalities in HPV-16-immortalized oral
epithelial cells,” Carcinogenesis, vol. 17, pp. 2003-2008 (1996).
Flaitz et al. “Molecular piracy: the viral link to carcinogenesis,” Oral
Oncol., vol. 34, pp. 448-453 (1998).
Recombinant DNA Advisory Committee, Minutes of Meeting March
8, 2001, U.S. Dept. of Health and Human Services (“RAC”).
Kaghad et al. “Monoallelically expressed gene related to p53 at 1p36,
a region frequently deleted in neuroblastoma and other human cancers” Cell,
vol. 90, pp. 809-819 (1997).
2
Page: Previous 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Next
Last modified: September 9, 2013